ROIV vs. RXRX

In the year-to-date period, ROIV achieves a -10.06% return, which is significantly higher than RXRX's -35.95% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ROIV Sharpe Ratio is -0.18, which is higher than the RXRX Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of ROIV and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ROIV nor RXRX has paid dividends to shareholders.

The maximum ROIV drawdown since its inception was -79.22%, smaller than the maximum RXRX drawdown of -90.39%. Use the drawdown chart below to compare losses from any high point for ROIV and RXRX. For additional features, visit the drawdowns tool.

This section allows you to compare key financial metrics between Roivant Sciences Ltd. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.